Table 1. Clinical and imaging characteristics for retrospective CS cohort.

Values are provided as means (SD), n (%), or median [Q1, Q3] as appropriate. P values were calculated with two-sided two-sample t test, chi-square test, Fisher’s exact test, or Kruskal-Wallis test.

	Missing	Overall	No clinical VT	Clinical VT	P
n		45	29	16
Demographic and clinical characteristics
Age (years)	0	54 (11)	54 (9)	53 (14)	0.674
Female sex	0	20 (44%)	16 (55%)	4 (25%)	0.102
Weight (kg)	1	91.8 (22.2)	89.2 (20.9)	96.6 (24.4)	0.327
Enhancement present on LGE-MRI	0	32 (71%)	18 (62%)	14 (88%)	0.094
Abnormal uptake on FDG-PET	0	32 (71%)	18 (62%)	14 (88%)	0.094
LVEF	0	50.6 (14.7)	52.0 (15.4)	48.1 (13.5)	0.376
QRS duration (ms)	3	114 (31)	107 (29)	126 (33)	0.079
Follow-up and clinical events
Time between MRI and PET (days)	4*	53 [28, 158]	55 [29, 161]	53 [18, 138]	0.808
Follow-up duration (days)	0	624 [244, 925]	600 [322, 847]	677 [100, 1071]	0.713
ICD implantation	0	16 (36%)	5 (17%)	11 (69%)	0.002
Appropriate shock	0	5 (11%)	0 (0%)	5 (31%)	0.004
Burden of disease remodeling (as % of myocardial volume)
Nondiseased	0	0.652 (0.251)	0.718 (0.235)	0.532 (0.241)	0.018
Fibrosis	0	0.153 (0.034)	0.144 (0.029)	0.170 (0.035)	0.019
Inflammation	0	0.236 (0.297)	0.163 (0.275)	0.368 (0.298)	0.031
Fibrosis-inflammation overlap	0	0.041 (0.054)	0.025 (0.044)	0.070 (0.058)	0.013
Fibrosis, excluding overlap with inflammation	0	0.112 (0.056)	0.119 (0.049)	0.100 (0.066)	0.328
Inflammation, excluding overlap with fibrosis	0	0.195 (0.248)	0.138 (0.233)	0.298 (0.248)	0.043

*Exact dates for both MRI and PET are unavailable for four patients because of heterogeneous deidentification procedures, but patients were only included in the study if it could be determined that their MRI and PET were acquired less than 1 year apart. No patients in the cohort experienced inappropriate shocks during follow-up.